TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, assays, instruments, and services in the United States, Taiwan, and China.
Excellent balance sheet and overvalued.
Share Price & News
How has TBG Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PG1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PG1 underperformed the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: PG1 underperformed the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is TBG Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is TBG Diagnostics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PG1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PG1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PG1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PG1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PG1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PG1 is good value based on its PB Ratio (0.3x) compared to the DE Biotechs industry average (3.2x).
How is TBG Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TBG Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine TBG Diagnostics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- TBG Diagnostics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has TBG Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PG1 is currently unprofitable.
Growing Profit Margin: PG1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PG1 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.
Accelerating Growth: Unable to compare PG1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: PG1 has a negative Return on Equity (-10.63%), as it is currently unprofitable.
How is TBG Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: PG1's short term assets (A$8.8M) exceed its short term liabilities (A$1.2M).
Long Term Liabilities: PG1's short term assets (A$8.8M) exceed its long term liabilities (A$88.5K).
Debt to Equity History and Analysis
Debt Level: PG1's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if PG1's debt to equity ratio has reduced over the past 5 years.
Inventory Level: PG1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: PG1's debt is covered by short term assets (assets are 38.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PG1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PG1 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -5.5% each year.
What is TBG Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PG1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PG1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PG1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PG1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PG1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
TBG Diagnostics has no CEO, or we have no data on them.
|Executive Chairman||0yrs||AU$80.00k||0.018% A$631.1|
|Chief Financial Officer||0yrs||AU$140.48k||no data|
|Company Secretary||3.2yrs||AU$36.00k||no data|
|Chief Operating Officer||1yrs||no data||no data|
|Chief Scientific Officer||14.1yrs||no data||no data|
|Head of Biology||0yrs||no data||no data|
|Head of Chemistry||0yrs||no data||no data|
|Head of Process Chemistry||0yrs||no data||no data|
|President of TBG (Xiamen) Inc||0yrs||no data||0.30% A$10.4k|
Experienced Management: PG1's management team is considered experienced (3.2 years average tenure).
|Executive Chairman||0yrs||AU$80.00k||0.018% A$631.1|
|Non-Executive Director||4.2yrs||AU$40.00k||0.23% A$7.9k|
|Non-Executive Director||4.2yrs||AU$40.00k||0.042% A$1.4k|
Experienced Board: PG1's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
TBG Diagnostics Limited's company bio, employee growth, exchange listings and data sources
- Name: TBG Diagnostics Limited
- Ticker: PG1
- Exchange: DB
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$5.657m
- Listing Market Cap: AU$3.434m
- Shares outstanding: 217.59m
- Website: https://www.tbgbio.com
- TBG Diagnostics Limited
- 138 Juliette Street
- Unit 6
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TDLA.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 2004|
|TDL||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jan 2004|
|PG1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 2004|
|TDL||ASX (Australian Securities Exchange)||NPV||AU||AUD||Feb 2016|
TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, assays, instruments, and services in the United States, Taiwan, and China. The company offers nucleic acid extraction, human leukocyte antigen (HLA) sequence specific primer typing, HLA sequence based typing, and HPA genotyping kits, as well as reagents and accessories; halotype HLA NGS products; equipment comprising nucleic acid extraction, automated pipetting, and gel electrophoresis systems; and HLA genotyping and contract manufacturing services, as well as reagents analysis software. It serves clinical labs of hospitals and independent reference labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. The company was incorporated in 1989 and is based in Greenslopes, Australia. TBG Diagnostics Limited is a subsidiary of Medigen Biotechnology Corporation.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 22:55|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.